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PENCIRIAN MOLEKULAR DAN PENGHASILAN PROTEIN REKOMBINAN YANG 
SPESIFIK UNTUK Shigella flexneri: KE ARAH PEMBANGUNAN UJIAN 
DIAGNOSTIK SEGERA BAGI PENYAKIT DISENTERI 
 
ABSTRAK 
 
Disenteri basilus atau juga dikenali sebagai shigelosis disebabkan terutamanya oleh 
bakteria Shigella. Shigelosis merupakan suatu penyakit yang serius di mana hampir 
165 juta penduduk dijangkiti setiap tahun. Ia merupakan infeksi enterik invasif yang 
biasanya mempunyai gejala seperti demam, sakit abdomen dan diarea berdarah.  S. 
flexneri merupakan spesies yang paling kerap dipencilkan dan biasanya menyebabkan 
shigelosis secara endemik di negara yang sedang membangun. Kaedah pengesanan 
rutin bergantung kepada teknik pengkulturan dan pengenalpastian Shigella spp. 
daripada tinja, adalah sukar dan memerlukan proses ujikaji yang cerewet, memakan 
masa 3 hingga 5 hari dan mempunyai sensitiviti yang rendah. Sehingga kini, tiada ujian 
diagnostik segera yang terdapat di pasaran bagi mengesan shigelosis. Oleh yang 
demikian, ujian diagnostik segera yang ringkas, sensitif dan spesifik perlu dibangunkan 
bagi mengesan jangkitan pada peringkat awal. Ujian diagnostik segera secara 
langsung akan membantu dari segi memberi pengendalian dan rawatan yang berkesan 
kepada pesakit serta dapat menyediakan strategi pencegahan awal perebakan 
penyakit yang sangat mudah ditularkan tersebut. Pembangunan ujian diagnostik 
segera berasaskan teknologi imunoasai generasi baru amat diperlukan supaya proses 
pengesanan dapat dilakukan di tepi katil pesakit dengan segera. 
 
Kajian terdahulu telah mengenalpasti satu protein yang antigenik dan spesifik pada 
Shigella spp. berberat molekul 35 kDa dan berpotensi dalam pengesanan jangkitan 
Shigella. Sehubungan dengan itu, tujuan utama kajian ini adalah untuk 
membangunkan parameter asas yang penting bagi menghasilkan protein rekombinan 
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yang tulen dalam kuantiti yang tinggi ke arah pembangunan ujian imunokromatografi 
segera bagi pengesanan segera jangkitan S. flexneri.  
 
Jujukan asid amino protein tersebut ditentukan dengan kaedah penjujukan asid amino. 
Seterusnya analisis homologi dilakukan terhadap pengkalan data jujukan lengkap 
genom S. flexneri untuk menentukan jujukan lengkap asid amino serta nukleotida gen 
yang mengkodkan protein 35 kDa tersebut. Hasil daripada analisis tersebut telah 
mengenalpasti gen yang mengkodkan protein ompA. Pengenalpastian protein tersebut 
seterusnya disahkan melalui teknik MALDI-ToF dan kehadiran peptida signal pada 
protein tersebut ditentukan. Plasmid rekombinan dihasilkan dengan menggunakan 
vektor pET 43.1 Ek/LIC untuk proses ekspresi protein rekombinan ompA di dalam E. 
coli. Klon rekombinan yang terhasil dipastikan mengandungi jujukan selitan yang betul 
dan proses ekspresi protein rekombinan dioptimakan bagi menghasilkan protein 
rekombinan yang antigenik dan spesifik dalam kuantiti yang tinggi. Kehadiran protein 
rekombinan ditentukan dengan menggunakan kaedah elektroforesis SDS-PAGE dan 
reaktiviti imun ditentukan dengan kaedah imunoasai blot Western. 
 
Protein rekombinan yang mempunyai histidin ditulenkan dengan menggunakan 
teknologi IMAC. Proses penulenan protein dilakukan secara kecil pada awal ujikaji dan 
seterusnya ditingkatkan dengan menggunakan sistem FPLC. Kaedah penulenan 
dioptimakan terlebih dahulu dan didapati 150 mM imidazole adalah mencukupi untuk 
mengeluarkan protein daripada resin. Protein berkepekatan lebih daripada 4.0 mg/ml 
telah dihasilkan dengan menggunakan kaedah ini dan lebih kurang 88 mg protein 
dapat diperolehi daripada 3 L kultur bakteria. Kajian ini berjaya menghasilkan 
maklumat asas yang penting dan berguna untuk strategi menghasilkan protein 
rekombinan yang tulen. 
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Protein yang telah ditulenkan digunakan untuk membangunkan satu ujian 
imunokromatografi segera bagi mengesan antibodi IgA yang spesifik di dalam serum 
pesakit yang dijangkiti dengan S. flexneri. Ujian ini berprinsip bahawa antibodi IgA 
yang spesifik terhadap protein rekombinan yang telah disembur di atas membran akan 
dikesan dengan partikel yang dikonjugat dengan emas. Intergrasi antigen OMP 
daripada S. flexneri di dalam ujian tersebut didapati memainkan peranan sebagai 
antigen kontrol dalaman. Kajian pengoptimuman dilakukan terhadap kepekatan antigen 
yang digunakan supaya sensitiviti dan spesifisiti yang maksimum diperolehi. 
Kepekatan protein rekombinan 1 mg/ml dan antigen OMP 4 mg/ml adalah kepekatan 
yang optimum bagi ujian tersebut memandangkan ujian tersebut memberikan reaksi 
positif dengan serum S. flexneri dan reaksi negatif diperolehi dengan serum dari 
pesakit yang dijangkiti dengan Salmonella typhi dan serum daripada individu sihat. 
Kajian ini menunjukkan bahawa kuantiti dan posisi antigen yang disembur adalah 
kritikal untuk memperolehi keputusan ujian yang sebenar. 
 
Kajian penilaian awal di dalam makmal dilakukan dengan menggunakan 56 serum dari 
pesakit yang dijangkiti dengan S. flexneri, jangkitan berkaitan yang lain serta serum 
daripada individu sihat. Ujian ini menghasilkan keputusan positif apabila 
ditindakbalaskan dengan ke semua serum daripada pesakit yang dijangkiti dengan S. 
flexneri (n=6) dan memberi keputusan negatif kecuali satu serum daripada individu 
sihat, apabila ditindakbalaskan dengan serum daripada pesakit yang bukan dijangkiti 
dengan S. flexneri (n=50). Berdasarkan keputusan penilaian terhadap ujian yang 
dibangunkan, ujian tersebut adalah spesifik terhadap pengenalpastian jangkitan S. 
flexneri dengan 100% sensitiviti, 98% spesifisiti, 85.7% PPV dan 100% NPV. Sebagai 
kesimpulan, asai yang dibangunkan tersebut mempunyai potensi diagnostik bagi 
pengesanan jangkitan S. flexneri. Walau bagaimanapun, kajian penilaian lanjutan yang 
menggunakan serum yang lebih banyak dari negara yang endemik perlu dilakukan 
untuk menentukan potensi sebenar ujian tersebut. 
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MOLECULAR CHARACTERIZATION AND PRODUCTION OF A SPECIFIC 
RECOMBINANT PROTEIN OF Shigella flexneri: TOWARDS DEVELOPMENT OF A 
RAPID IMMUNOCHROMATOGRAPHY DIAGNOSTIC TEST FOR DYSENTERY 
 
ABSTRACT 
 
Bacillary dysentery is caused mainly by infection with Shigella spp. which is also known 
as shigellosis. It remains a common and serious health problem throughout the world 
and has been estimated to infect about 165 million people worldwide annually. It is an 
acute invasive enteric infection often characterized by abdominal pain, fever and 
bloody diarrhea. S. flexneri is the most frequently isolated species causing endemic 
shigellosis in developing countries. The current method of diagnosis still depends on 
the traditional culture method, which is laborious, relatively insensitive and takes 3 to 5 
days to produce result. To date, no rapid diagnostic methods are available 
commercially. Hence there is a need to develop a rapid, simple, sensitive and specific 
diagnostic test, which can diagnose S. flexneri at early stages of infection. A rapid and 
reliable diagnostic assay would significantly improve effective treatment, management 
and control of this highly infectious bacterium. There is a need for the development of 
the next generation immunoassay platform which provides a more rapid, sensitive and 
portable point-of-care assay. 
 
In the effort to improve the diagnosis of shigellosis, a specific and antigenic protein of 
35 kDa in size has been previously identified which has a diagnostic potential for 
detection of Shigella infections. The aim of this study was to develop important 
fundamental parameters to generate sufficient amounts of purified recombinant 35 kDa 
protein and to exploit its application in developing a rapid dipstick test, as an alternative 
diagnostic test for the detection of anti-S. flexneri IgA antibody. 
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The N-terminal amino acid sequences encoding the 35 kDa protein were determined 
by amino acid sequencing and subsequently homology search was performed against 
the S. flexneri genome sequence database to determine the complete amino acid and 
nucleic acid sequences. The identified ompA protein was validated by MALDI-ToF 
technique and presence of signal peptide was determined. A recombinant plasmid was 
constructed using pET 43.1 Ek/LIC vector for the expression of the recombinant ompA 
protein in E. coli. This recombinant clone was verified to contain the appropriate insert 
and important parameters were optimized to express the target protein in E. coli BL21 
(DE3) to generate high concentrations of soluble, antigenic and specific recombinant 
protein. The target protein was verified by SDS-PAGE analysis and immunogenicity 
was determined by Western blot technique.  
 
The recombinant protein was over-expressed and the histidine-tagged protein was 
purified using IMAC technology. Small-scale protein purification was performed initially 
using a batch column technique and consequently was up-scaled using FPLC system 
to generate high concentrations of purified protein in a large quantity. The purification 
parameters were optimized and the 150 mM of imidazole was sufficient to elute the 
target protein. Protein concentration above 4.0 mg/ml was generated and 
approximately 88 mg of total protein was eluted from 3 L of bacterial culture using the 
optimized procedure. This study provided important fundamental information useful for 
devising strategies to purify the soluble recombinant protein. 
 
The purified recombinant protein was used to develop a rapid dipstick test for the 
detection of specific IgA antibody in sera from patients infected with S. flexneri. The 
test is based on the principle that the IgA antibodies against immobilized purified 
recombinant ompA antigens on a membrane are detected by a colloidal gold particle 
technique. Incorporation of OMP antigen of S. flexneri served as the internal control 
antigen in the dipstick test. Different concentrations of antigens were lined to obtain 
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maximum sensitivity and specificity. The recombinant protein concentration of 1 mg/ml 
and OMP concentration of 4 mg/ml was selected in this study since the test strip gave 
positive reactions when probed against the S. flexneri sera and produced negative 
reactions when probed against the non-S. flexneri sera. This study demonstrated that 
the positions and the amount of the antigens lined in the Test Line are critical in 
obtaining a true positive result. 
 
A preliminary laboratory evaluation was carried out using 56 sera from patients with S. 
flexneri infections, other related infections and healthy individuals’ sera. The test 
produced positive results in all patients infected with S. flexneri (n=6) and was found 
negative in all except one of the sera from non S. flexneri cases (n=50). This test was 
found to be specific in recognizing S. flexneri infections with 100% sensitivity, 98% 
specificity, 85.7% positive predictive value and 100% negative predictive value. The 
results of this assay showed promise with high reliability and accuracy and capable of 
discriminating non-S. flexneri cases in an endemic area. It includes benefits of user-
friendly format that is rapid, simple, reliable, with built-in control and relatively 
inexpensive. In conclusion, the dipstick test has a diagnostic value and is a useful 
method when it is used together with the bacteriological gold standard culture methods 
in the diagnosis of this highly contagious disease. However, further studies with a 
larger set of patients from various endemic areas need to be investigated to evaluate 
the true performance of this dipstick test. 
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Abstract 
 
Shigella flexneri is highly infectious agent that is transmitted by the faecal oral route. It is 
the most common etiological agent of bacillary dysentery contracted especially among 
children in developing countries. The current laboratory detection method is by culturing 
the patients’ stool onto selective media. However, the major limitations of the culture 
method are low isolation rate, time-consuming and labour-intensive. The development of a 
rapid detection method for Shigella would greatly benefit the disease control and patient 
management. In an earlier study, ompA protein of Shigella flexneri exhibited high 
antigenicity and specificity. The purpose of this study was to produce recombinant ompA 
protein of Shigella flexneri and to use it to develop a rapid test to detect Shigella flexneri in 
patients’ specimens. The specific protein was cloned and expressed to generate sufficient 
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amount of protein for the development of a specific test. PCR cloning was performed using 
pET Ek/LIC 43.1 vector and the specific recombinant protein was expressed in BL21 E. 
coli expression host. Protein expression profile was visualized via SDS-PAGE and 
antigenicity of the recombinant protein was determined using Western blot technique. The 
histidine-tagged protein was purified using the standard immobilized metal affinity 
chromatography technique (IMAC). The purified recombinant ompA protein was 
immobilized on a nitrocellulose membrane attached to a plastic film and cut into strips. The 
test strips were used to detect specific immunoglobulin A in the patients’ sera by means of 
immunochromatography technique using gold conjugated anti-human IgA. Nucleotide 
sequence of the recombinant plasmid revealed an open reading frame encoding the 
appropriate ompA protein. Based on the SDS-PAGE analysis, the recombinant protein 
tagged with the NusA fusion protein had a molecular mass of about 100 kDa. The ompA 
protein was expressed abundantly in soluble form and was purified to near homogeneity. 
The protein was antigenic when probed with mouse polyvalent sera raised against the 
native ompA protein, as well as sera from patients infected with S. flexneri. 
Immunochromatography test was developed and optimized with sera from patients 
infected with S. flexneri as well as sera from other related infections. This preliminary study 
showed that the immunochromatography test developed is simple and rapid. This test can 
play a useful role as a complementary test in the diagnosis of S. flexneri infection. 
However, further  optimization are required to improve its performance. 
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Introduction 
Shigella flexneri is the most common etiological agent of bacillary dysentery contracted 
especially among children in developing countries. The current laboratory detection 
method is by culturing the patients stool onto selective media. However, this pathogenic 
bacterium may be present in low numbers in stool and the culture method is time-
consuming and labour-intensive. 
 
Objectives 
Development of a specific diagnostic test requires the use of a specific antigen. In an 
earlier study, ompA protein of Shigella flexneri exhibited high antigenicity and specificity. 
The purpose of this study was to clone, express and purify the ompA protein of Shigella 
flexneri.  
 
Methods 
PCR cloning was performed using pET Ek/LIC 43.1 vector and the specific recombinant 
protein was expressed in BL21 E. coli expression host induced with 1 mM IPTG. Protein 
 247
expression profile was visualized via SDS-PAGE and antigenicity of the recombinant 
protein was determined using Western blotting technique. The histidine-tagged protein 
was purified using the standard immobilized metal affinity chromatography technique 
(IMAC).  
 
Results 
Nucleotide sequence of the recombinant plasmid revealed an open reading frame 
encoding the appropriate ompA protein. Based on the SDS-PAGE analysis, the 
recombinant protein tagged with the NusA fusion protein had a molecular mass of about 
100 kDa. The ompA protein was expressed abundantly in soluble form and was purified to 
near homogeneity using native conditions with 250 mM imidazole in the elution buffer. The 
protein was antigenic when probed with mouse polyvalent sera raised against the native 
ompA protein extracted from Shigella flexneri, as well as patients sera infected with S. 
flexneri when tested against IgA. 
 
Discussion and conclusion 
The production of large quantities of recombinant ompA protein using the expression and 
purification protocol described above would be useful for development of rapid detection 
test, crystallographic analysis, studies of pathogen-receptor interactions and potential for 
vaccine design. 
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Abstract 
 
 
Conventional laboratory diagnosis of shigellae (stool culture method) is relatively 
inefficient, time-consuming and laborious. Development of a specific diagnostic test 
requires the use of a specific antigen. In our earlier study, a specific and antigenic 
membrane protein of Shigella flexneri was determined. Purpose of this study was to 
characterize, clone and express the specific membrane protein. PCR cloning was 
performed using pET Ek/LIC 43.1 vector and the specific recombinant protein was 
expressed in BL21 E. coli expression host induced with 1 mM IPTG. Protein expression 
profile was visualized via SDS-PAGE and antigenicity of the recombinant protein was 
determined using Western blotting techniques. Based on the SDS-PAGE analysis, the 
protein of interest was expressed abundantly in soluble form, in which majority of the 
protein was in the supernatant of the sonicated lysed cells. The molecular size of the 
recombinant protein tagged with the NusA fusion protein was estimated at ~100 kDa. 
Nucleotide sequence of the recombinant plasmid revealed an open reading frame 
encoding the appropriate specific protein. Further analysis indicated that the protein 
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contained a 21 N-terminal amino acid residue predicted to be a signal peptide. The protein 
was antigenic when probed with mouse polyvalent sera raised against the native 
membrane protein extracted from Shigella flexneri, as well as patients infected with S. 
flexneri when tested against IgA. 
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Abstract 
 
Shigella is the most common etiological agent of bacillary dysentery contracted mainly 
among children in developing countries. Advances in bioinformatics tools are important for 
identification of partial or complete gene and protein sequence. In our previous study, we 
have identified a specific membrane protein against IgA in patients infected with Shigella 
flexneri and Shigella sonnei. Aim of this study is to determine the complete sequence of 
the gene encoding the specific protein for Shigella flexneri and Shigella sonnei. The pre-
fractionation of membrane protein was performed by SDS-PAGE and the specific band 
was eluted via electro-elution. The purified protein from pre-fractionation was subjected to 
SDS-PAGE followed by electroblotting onto PVDF membrane for N-terminal amino acid 
sequencing. Homology search was performed for the amino acid sequence using BLAST 
at url: ncbi.nlm.nih.gov/BLAST and the complete gene sequence encoding the specific 
protein was identified as ompA gene of Shigella flexneri. To determine the gene encoding 
for the similar membrane protein in Shigella sonnei, PCR was performed with primers 
designed at 100 bases flanking of the gene with pfu polymerase and Shigella sonnei 
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genomic DNA as the PCR template. The purified PCR product was sequenced and the 
complete gene sequence was determined. We found that the gene sequence of S. sonnei 
is about 96% similar to S. flexneri ompA gene. Both gene sequences for S. flexneri and S. 
sonnei were submitted to GeneBank with accession numbers AY305875 and AY305874 
respectively. 
 
 1
CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Introduction to Shigella 
1.1.1 History and significance of Shigella discovery 
Shigella is a Gram-negative bacterium that causes bacillary dysentery or also known 
as shigellosis. Shigellosis is an acute invasive enteric infection often characterized by 
abdominal pain, fever and bloody diarrhea (dysentery). Isolation of this bacterium from 
faeces of individuals with acute dysentery was first described by Chantemesse and 
Widel in 1888 (reviewed by Lan & Reeves, 2002). A detailed description of the 
organism that caused the dysentery was reported by Shiga in 1898 and named the 
organism as Bacillus dysenteriae. In late 1940, the genus Shigella was classified into 
four species; Shigella dysenteriae, Shigella flexneri, Shigella boydii and Shigella sonnei 
which were also known as Shigella subgroups A, B, C and D respectively (Ewing, 
1986). 
 
In the earlier classification, Shigella and Escherichia coli were classified in the same 
genus because of their genetic similarity.  Recently, a comparative genomic study 
between the two organisms revealed that 175 of the total 3235 open reading frames 
were exclusive for S. flexneri (Wei et al., 2003). However, Shigella strains were put in a 
different genus from E. coli because of their medical significance, human host 
interactions, pathogenicity, physiology (failure to ferment lactose or decarboxylate 
lysine) and serological characteristics (Escobar-Paramo et al., 2003). 
 
Shigellosis remains a common and serious health problem throughout the world 
(Echeverria et al., 1992; Oyofo et al., 2002; Kimura et al., 2004). The global burden of 
Shigella infection was estimated by analyzing the number of cases worldwide 
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according to the world’s population as categorized into developed and developing 
countries and into age groups (Kotloff et al., 1999). This study found that the annual 
number of Shigella episodes throughout the world was 164.7 million, of which 163.2 
million occurred in developing countries, with 1.1 million deaths. Sixty-nine percent of 
the episodes and 61 percent of all shigellosis-related deaths involved children younger 
than 5 years of age. Shigellosis is endemic in many developing countries and 
occasionally occurs as an epidemic. S. dysenteriae serotype 1, also known as the 
Shiga bacillus has been recognized as the major cause of epidemic dysentery. S. 
sonnei and S. boydii usually causes relatively mild illness in which diarrhea may be 
watery or bloody. S. flexneri is the main cause of endemic shigellosis in developing 
countries (Faruque et al., 2002; Lee & Puthucheary, 2003; Niyogi & Pazhani, 2003). 
 
1.1.2 Epidemiology of shigellosis 
Shigellosis is a global human health problem. It is the most important cause of bloody 
diarrhea worldwide, especially in developing countries with substandard hygiene and 
poor quality of water supplies (Stoll et al., 1982; Bennish & Wojtyniak, 1991; Niyogi, 
2005). Shigellosis is endemic in numerous developing countries (Echeverria et al., 
1991; Clemens et al., 1999). Various studies carried out in developing countries 
showed that Shigella is associated with 5% to 15% of the diarrheal cases and 30% to 
50% of dysentery cases (Echeverria et al., 1991; Faruque et al., 2002). Endemic 
Shigella is responsible for approximately 10% of all diarrheal episodes among children 
younger than five years living in developing countries (Bennish et al., 1990; Kotloff et 
al., 1999). 
 
The global burden was determined from various locations estimated that shigellosis 
accounts for 164.7 million cases, of which 99% (163.2 million cases) occurred in 
developing countries (Kotloff et al., 1999). The burden of shigellosis in Asia was 
estimated from published studies that were initiated in Asian countries. The annual 
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number of Shigella episodes and deaths in Asia was estimated to be 91 million and 
414 000 respectively. S. flexneri is the most common serotype, followed by S. sonnei 
(WHO, Weekly Epidemiological Report, 2005). In Bangladesh, dysentery due to 
Shigella causes 75 000 deaths among children annually during peak epidemic years 
and estimated 35 000 deaths occur during non-epidemic years (Bennish & Wojtyniak, 
1991). In general, both the incidence and the fatality rates are highest among very 
young children and the elderly. The highest incidence of shigellosis is in young 
children, usually those ages less than 5 years (Taylor et. al., 1986; Bennish et al., 
1990; Minh et al., 1998; Kotloff et al., 1999; Vargas et al., 2004). 
 
S. flexneri has been the most frequently isolated species in developing countries 
(Taylor et. al., 1991; Faruque et al., 2002; Niyogi & Pazhani, 2003). S. flexneri serotype 
2a was found to be the major endemic serotype in developing countries (Kotloff et al., 
1999). The median percentages of isolates of S. flexneri, S. sonnei, S. boydii and S. 
dysenteriae were 60%, 15%, 6%, and 6% respectively, in developing countries; and 
16%, 77%, 2%, and 1% respectively, in developed countries (Kotloff et al., 1999). A 
case-control study to characterize the epidemiology of bloody diarrhea in rural Western 
Kenya reported that 80% of the bacterial pathogens isolated were due to Shigella spp., 
of which approximately 49% was caused by S. flexneri (Brooks et al., 2003). Another 
study in Pakistan reported that Shigella spp. were a more commonly occurring enteric 
pathogen in children having diarrhea and showed that S. flexneri was the most 
frequently identified species compared with S. dysenteriae, S. boydii and S. sonnei. 
(Khalil et al., 1998). A study in Bangladesh reported that the fatality rate for 970 
inpatients with shigellosis was 11%, with most deaths occurred among malnourished 
children infected with S. flexneri (Bennish & Wojtyniak, 1991). Studies have also 
reported that Shigella is one of the most important pathogen causing traveller’s 
diarrhea (Jiang et al., 2002; Ruiz et al., 2002). It has been reported that approximately 
580 000 travellers from industrialized countries are infected annually (Kotloff et al., 
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1999). In the United States and Europe, children in day-care centres, migrant workers, 
travellers to developing countries are frequently infected (Niyogi, 2005). Shigella spp. 
continue to be responsible for morbidity and mortality in high-risk populations such as 
children under five years of age, senior citizens, toddlers in day-care centres and 
people with a weakened immune system. Rapid spread occurring in closed 
environments, such as day care centres have been reported (Weissman et al., 1975; 
Chiou et al., 2001). Outbreaks are more associated with contaminated water, food, 
overcrowding communities, food handlers and flies (Kapperud et al., 1995; Shears, 
1996).  
 
A study by Lee & Puthucheary (2002) on bacterial enteropathogens in childhood 
diarrhea in a Malaysian urban hospital showed that Shigella spp. was the third most 
common bacteria isolated from stool samples. This retrospective study conducted 
among children admitted with diarrhea in University of Malaya Medical Centre (UMMC), 
Kuala Lumpur, from 1978 to 1997, reported that Shigella spp. was isolated from 1.4% 
(386 isolates) of total stool specimens, corresponding to 13% of the 2986 isolates 
positive for bacterial pathogens. S. flexneri was found to be the most frequently 
isolated species reported which constituted 74% of all Shigella isolates (Lee & 
Puthucheary, 2003). Another retrospective analysis conducted among children 
admitted to the Hospital USM, Kelantan, Malaysia, showed that the isolation rate of S. 
flexneri was 2.28% out of the 1097 stool samples studied (Ludin et al., 2003). Not 
much information was available for the prevalence of shigellosis in other parts of 
Malaysia 
 
1.1.3 Classification 
The genus Shigella belongs to the tribe Escherichia in the family Enterobacteriaceae. 
The four species of Shigella are subdivided into serotypes based on the O antigen 
component of lipopolysaccharide present on the outer membrane of the cell wall: S. 
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dysenteriae (consisting of 13 serotypes), S. flexneri (consisting of 8 serotypes), S. 
boydii (consisting of 18 serotypes) and S. sonnei (single serotype). S. flexneri is 
subdivided into eight serotypes that are 1, 2, 3, 4, 5, 6, X and Y, with eleven sub-
serotypes that are 1a, 1b, 1c, 2a, 2b, 3a, 3b, 4a, 4b, 5a and 5b. 
 
1.1.4 Properties of Shigella 
1.1.4.1 Physical characteristics 
It is a small, non-spore forming rod with a diameter of 0.3 to 1 µm and a length of 1 to 6 
µm. It is Gram-negative, non-motile (no H antigens), non-capsulated and possess the K 
and O antigens. O antigen (somatic antigen) is useful in serological identification to 
classify the four species. K antigen is the capsule antigen which occasionally interferes 
with O antigen determination. Shiga toxin, also called as verotoxin, is produced by 
Shigella dysenteriae type 1. The toxin has a molecular weight of 68 kDa. It is a multi-
subunit protein made up of an A subunit (32 kDa), responsible for toxic action of the 
protein and five molecules of the B subunit (7.7 kDa), responsible for binding to a 
specific cell receptor.  
 
1.1.4.2 Growth and culture characteristics 
Shigella is a facultative anaerobe bacterium and is able to grow at temperatures 
ranging from 12°C to 48°C (optimum 37°C), at a pH range of 5.0 to 7.3 (Tetteh & 
Beuchat, 2003; Zaika & Phillips, 2005). Generally, deaths of Shigella are enhanced 
with increased in temperature, decreased in pH and increased in NaCl concentrations. 
The organism is acid resistant and can easily pass the gastric acid barrier. 
The common selective/differential agar media used for the recovery of Shigella are 
MacConkey (MAC), Xylose Lysine Deoxycholate (XLD), Hektoen (HEK) and 
Salmonella-Shigella (SS) and Deoxycholate Citrate Agar (DCA). It has typical non-
lactose fermenting characteristic colonies on lactose enriched media such as on MAC, 
DCA and SS agar. Shigella is resistant to bile salts and this characteristic is usually 
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useful in the selective media. Colonies on the MacConkey and DCA agar appears to be 
large, 2 to 3 mm in diameter, translucent and colourless (non-lactose fermenting). 
Whereas, on the XLD agar, colonies appear to be much smaller (1 to 2 mm diameter) 
and red in colour as lysine is decarboxylated producing alkaline end products which 
raises the pH and cause the agar to turn into deep red colour. Shigella does not 
produce hydrogen sulphide (H2S) on the XLD, HEK and SS agar. 
 
1.1.4.3 Biochemical characteristics 
Shigella is biochemically much less reactive than their close relatives, members of the 
genus Escherichia (Ewing, 1986). Shigella does not ferment lactose but cultures of S. 
sonnei utilize this substrate after 24 hours incubation. Shigella utilizes glucose and 
other carbohydrates, producing acid but not gas (with the exception of S. flexneri 6) 
and is oxidase negative. Normally, indole is not produced and methyl red (MR) test is 
positive. Lysine is not decarboxylated and ornithine is decarboxylated only by S. sonnei 
and S. boydii. Serogroups A, B and C are very similar biochemically while S. sonnei 
can be differentiated from the other serogroups by positive beta-D-galactosidase and 
ornithine decarboxylase biochemical reactions. Neither citrate nor malonate is used as 
the sole carbon source for growth, and the organisms are inhibited by potassium 
cyanide. 
1.2 Clinical manifestations, pathogenesis, treatment and prevention of 
shigellosis 
1.2.1 Reservoirs and mode of transmission 
Humans and primates are the only natural hosts for Shigella. The predominant mode of 
transmission is by faecal-oral route, in which Shigella is usually transmitted from 
person to person and occurs in areas where personal hygiene is poor (Smith, 1987; 
Shears, 1996; Chiou et al., 2001; Chen et al., 2003). Part of the reason for the 
efficiency of transmission is because Shigella is highly infectious, as 10 to 200 
organisms are sufficient to cause infection (DuPont et al., 1989). This infective dose of 
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Shigella is lower than that reported for most other enteric pathogens such as for Vibrio 
spp. and Salmonella spp. which require at least 104 to 105 organisms to cause 
infection. The low infectious dose suggests that Shigella are capable of surviving in 
highly acidic environments such as in gastric secretions (Gorden & Small, 1993; Lin et 
al., 1995; Waterman & Small, 1998). 
 
Shigellosis is usually acquired from consumption of contaminated food and water 
(Islam et al., 1993; Villalobo & Torres, 1998). It is usually acquired by eating food that 
has become contaminated by infected food handlers (Rosalie et al., 1999), 
consumption of raw vegetables harvested in fields where sewage was used as fertilizer 
(Sur et al., 2004) or associated with eating oysters (Terajima et al., 2004). 
Transmission also occurs through contaminated fomites or by accidentally drinking 
contaminated water in the swimming pools (Shears, 1996; Fleming et al., 2000). In 
certain settings where disposal of human faeces is inappropriate, flies, particularly 
Musca domestica, may serve as vectors for the transmission of shigellosis (Alan & 
Olsen, 1998; Todar, 2005). During dysentery, Shigella are excreted in large numbers in 
the stool, up to 106 to 1010 bacteria per gram of stool (Rowe, 1990). The organism can 
be found in the faeces for weeks after symptoms have ceased (Sur et al., 2004). 
Shigella have been documented to survive in soiled linen for up to seven weeks, in 
fresh water for 5 to 11 days, in salt water for 12 to 30 hours, in dust at room 
temperature for 6 weeks, in sour milk for 4 weeks and in kitchen refuse for 1 to 4 days 
(reviewed by Todar, 2005). 
 
1.2.2 Incubation period 
The incubation period is 1 to 4 days, which is usually followed by the sudden onset of 
acute symptoms (Hale & Formal, 1987). In mild cases, the disease may be self limiting 
but severe cases require appropriate medication. Shigellosis usually resolves within 5 
to 7 days (Hale et al., 1991).  
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1.2.3 Pathogenesis and immune responses 
Shigella infection is generally limited to the intestinal mucosa. Pathogenesis involves 
the penetration of the bacterium into the epithelial M cells of the colon (LaBrec et al., 
1964; Mantis et al., 1996). Shigella uses the type III secretion system to invade the 
epithelium cells and involves approximately 20 proteins which are encoded by the 210 
kb virulent plasmid (Maurelli & Sansonetti, 1988; Suzuki & Sasakawa, 2001; Mavris et 
al., 2002a; Mavris et al., 2002b). Among the proteins secreted are VirA, OspB to OspG 
and invasion plasmid antigens (Ipa) proteins such as IpaB, IpaC, IpaD and IpaH.  
 
The ability to cross the epithelial lining, induce apoptosis of phagocytic cells, escape 
into the cytoplasm of epithelial cells and followed by cell-to-cell spread is the key 
determinant of the disease that elicited acute inflammatory reaction (Anand et al., 
1986; Sansonetti et al., 1995; Islam et al., 1997). The pathogenic mechanism of 
shigellosis is complex and has been studied extensively by Sansonetti and colleagues 
(Goldberg & Sansonetti, 1993; Sansonetti et al., 1996). 
 
Besides the development of acute inflammation, the adaptive immune response is 
elicited to provide protection against the infection (reviewed by Phalipon & Sansonetti, 
2003). Shigella is not an obligatory intracellular pathogen, thus the humoral immunity 
response is largely due to its extracellular activity. IgA is secreted by IgA secreting 
plasma cells in the lamina propria of submucosal layer. It is then endocytosed through 
the polymeric immunoglobulin receptor (pIgR), which is then transported through the 
mucosal epithelial cells into the mucosal secretions as secretory IgA (sIgA) [Lamm, 
1998]. In serum, IgA exist predominantly in monomer form, whereas in mucosal 
secretions it is mostly in dimers form (two monomeric IgA units linked by a J chain), 
mainly in the form of sIgA (present with a secretory component).   
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Studies have reported that the circulating IgA antibody secreting-cells (ASC) were 
significantly higher in the S. flexneri infected patients 5 to 7 days after the onset of the 
disease (Minh et al., 1996; Rasolofo-Razanamparany et al., 2001). Although the 
mechanism of immunity against shigellosis remains unclear, it has been reported that 
natural and experimental infections with Shigella elicited specific systemic and mucosal 
immune responses (Cohen et al., 1989, Cohen et al., 1991, Robin et al., 1997). The 
highest IgA and IgG titres were seen 1 week and 2 weeks after the onset of diarrhea, 
respectively (Van De Verg et al., 1996). Several studies have suggested that serum 
IgA reactivity reflected that of intestinal IgA since these antibodies were derived from 
the same source (Oberhelman et al., 1991; Van De Verg et al., 1996). A study 
conducted by Minh and colleagues (1996) showed that patients infected with S. flexneri 
had significantly higher serum IgA and IgG titres against LPS and Ipa proteins 
compared to the healthy controls, at day 4 after the onset of diarrhea and prolonged for 
2 weeks. The highest serum IgA and IgG titres were seen on day 7 and day 14 after 
the onset of diarrhea, respectively. This study also found that S. flexneri infected 
patients developed intestinal sIgA responses against these antigens, which significantly 
increased 4 days after the onset of diarrhea and reached its peak in 2 weeks. The IgA 
antibody was reported to be most frequently detectable between 10 and 20 days after 
the onset of infection (Oberhelman et al., 1991). 
 
1.2.4 Clinical signs and symptoms 
Clinically, the disease begins within 24 to 48 hours of ingestion of the organism (Hale 
et al., 1991). Shigellosis is characterized by frequent small volume passage of stools 
that consist largely of blood, mucus and pus, accompanied by fever and stomach 
cramps. Blood, mucus and pus cells in the stools are the signs of colorectal 
inflammation (Li, 2000). These symptoms are also common in infections caused by 
Campylobacter, Salmonella and Entamoeba histolytica, but usually generate self-
limited illness that is rarely as serious as shigellosis. Apart from bloody stools, patients 
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with dysentery often have rectal pain, fatigue, malaise and anorexia.  However, in some 
cases, Shigella causes acute non-bloody diarrhea that cannot be distinguished clinically 
from diarrhea caused by other enteric pathogens. Shigellosis can be serious in some 
cases, especially involving young children and the elderly, which require hospitalization 
of the patients. Severe cases may become life threatening and contribute to substantial 
mortality. Severe infections with high fever have been associated with seizures among 
children (Khan et al., 1999). Patients with severe infection may pass more than 20 
dysenteric stools in one day. Dysentery is also characterized by the daily loss of 200-
300 ml of serum protein into the faeces, which exacerbates malnutrition and growth 
stunting in young children living in developing countries (Alam et al., 2000). Depletion 
of immune system also increases the risk of shigellosis and contributes to substantial 
mortality (Simor et al., 1989; Gassama et al., 2001). Clinical symptoms usually persist 
for 10 to 14 days or longer (Li, 2000). The use of clinical signs and symptoms is 
therefore very important in helping to identify patients with shigellosis. 
 
1.2.5 Complications 
Most episodes of shigellosis in healthy individuals are self-limited and resolve without 
sequelae. Life-threatening complications are most often seen in malnourished infants 
and young children living in developing countries, the elderly and people who have a 
weakened immune system (Bennish & Wojtyniak, 1991; Baer et al., 1999; Alam et al., 
2000; Gassama et al., 2001). Complications include metabolic derangements, such as 
dehydration, hyponatraemia, hypoglycaemia, hypoproteinaemia and severe anorexia 
intestinal complications such as toxic megacolon, rectal prolapsed and intestinal 
perforation (Bennish & Wojtyniak, 1991; Ashkenazi, 2004). Bacteraemia due to 
Shigella is relatively rare but does occur (Strulens et al., 1985; Heyking & McInintosh 
1997). Bacteraemia due to Shigella have been reported to be common among HIV-
infected and other immunocompromised patients (Batchelor et al., 1996). Persistent 
diarrhea and malnutrition are the most common chronic sequelae (Niyogi, 2005). Other 
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complications seen primarily in adults following infection with S. flexneri are reactive 
inflammatory arthritis (Gaston, 2005; Hannu et al., 2005), conjunctivitis and urethritis 
which is known as Reiter’s syndrome which occurs most commonly in adults with HLA-
B27 histocompatibility antigen (Finch et al., 1986). A variety of unusual extraintestinal 
manifestations may occur. Some children under 2 years can have neurological 
symptoms, including febrile seizures which usually occur in the presence of fever 
(Ashkenazi, 2004). Microangiopathic haemolytic anaemia can complicate infection with 
Shiga toxin-producing organisms, manifesting as the haemolytic uraemic syndrome 
(HUS) in children and as thrombotic thrombocytopenic purpura in adults (Koster et al., 
1978). Shigella has also been associated with chronic vulvovaginitis in children 
(Namdari et al., 2002). 
1.2.6 Treatment and prevention 
Though fluid and electrolyte replacement by either oral hydration or intravenous fluid 
therapy is the treatment of choice for acute diarrhea, antibacterial agents are indicated 
for treatment of suspected shigellosis. Antibiotic treatment for Shigella infection is 
recommended to decrease the duration of illness and person-to-person spread. 
Treatment in malnourished children especially in the developing countries is likely to 
reduce the risk of worsening malnutrition morbidity following shigellosis. Treatment is 
critical in the young children, the elderly or persons with chronic diseases, as 
shigellosis can be severe and lead to dehydration and other complications. 
 
The main antibiotics used are ampicillin, tetracycline, amoxicillin, cotrimoxazole, 
chloramphenicol and trimethoprim-sulfamethoxazole. However, treatment has become 
increasingly difficult due to emerging resistance to these commonly prescribed 
antibiotics (Martinez-Salazar, 1986; Salam & Bennish, 1991; Replogle et al., 2000). A 
study using 369 isolates showed that 59% were resistant to trimethoprim-
sulfamethoxazole, 63% were resistant to ampicillin, 85% were resistant to tetracycline, 
1% was resistant to cefixime, and 0.3% was resistant to nalidixic acid and none of the 
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isolates were resistant to ciprofloxacin (Replogle et al., 2000). Ciprofloxacin and 
nalidixic acid are now recommended as the first line treatment for Shigella infection. 
Many recent studies have reported multi-resistant strains to the commonly prescribed 
antibiotics occurring in the developing and developed countries (Replogle et al., 2000; 
Taneja et al., 2004). The Shigella resistance locus (SRL), have been identified in 
Shigella strains which mediates resistance to antibiotics (Turner et al., 2001; Turner et 
al., 2003). In Malaysia, out of 241 isolates tested for antibiotic sensitivity, 58% were 
resistant to at least one antibiotic, and 42% were multi-resistant to three or more 
antibiotics (Lee & Puthucheary, 2003).  
 
The spread of Shigella from an infected person to other persons can be stopped by 
increasing the personal hygiene. Hand washing with soap, safe disposal of human 
waste as well as safe food handling and processing are the basis of personal hygiene 
that will minimize the transmission of Shigella. 
 
1.3 Diagnosis of shigellosis 
1.3.1 Clinical diagnosis 
Clinical diagnosis of shigellosis is not specific. The diarrhoeal stage of the infection 
cannot be distinguished clinically from other bacterial, viral and protozoan infections 
(Youssef et al., 2000). The presence of fever suggests an invasive pathogen. Fever is 
not usually associated with organisms that act solely by means of enterotoxin 
production, so this finding is helpful for narrowing down the number of organisms under 
consideration. Patients presenting with watery diarrhoea and fever should be 
suspected of having shigellosis (Echeverria et al., 1991; Goodman & Segreti, 1999). 
Studies have reported that the height of the fever correlated with the severity of the 
illness (Mackowiak et al., 1992). The typical clinical feature of shigellosis is bloody and 
mucoid stool, but the differential diagnosis should include infection caused by 
enteroinvasive Escherichia coli (EIEC), Salmonella enteritidis, Campylobacter species 
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and Entamoeba histolytica (Goodman & Segreti, 1999; Sur et al., 2004). Usually, fresh 
and bright red blood is present in the stools of patients infected with Shigella rather 
than dark brown blood in Entamoeba histolytica infections (Niyogi, 2005). 
 
1.3.2 Laboratory diagnosis 
1.3.2.1 Haematology 
The total white blood cell count is often within reference range. However, in some 
cases, leucopenia, anaemia and thrombocytopenia may occur. 
1.3.2.2 Bacteriology 
1.3.2.2.1 Stool examination 
Macroscopic examination of stool characteristics such as for consistency (liquid, 
semisolid or formed stool) and atypical components (mucus, blood, non-bloody stools) 
are the key features in determining the potential pathogens causing the diarrhea. 
Moreover, routine microscopic examinations for the presence of red and white blood 
cells are important characteristics in establishing the diagnosis of dysentery. Fresh and 
unstained suspension of faeces is examined directly under the microscope. Invasion of 
the intestinal wall and the consequent inflammatory reaction resulted in the infiltration 
of the polymorphonuclear leukocyte and red blood cells in the faecal secretion. Studies 
have demonstrated that faecal blood or leukocytes are detectable in the stool in 
approximately 70% of shigellosis cases, whereas both faecal blood and leukocytes are 
detected in approximately 50% of cases (Echeverria et al., 1991). However, 
confirmation of laboratory diagnosis is achieved by stool culture. 
 
1.3.2.2.2 Stool culture 
Stool culture is the method of choice. A definite diagnosis of Shigella infection is made 
by isolating the organism from stool specimens and serotyping the isolate. Culture is 
also required for antibiotic susceptibility testing. Fresh stool samples collected from 
patients before initiation of antibiotic therapy are preferred for microbiological tests 
 14
because the chances of recovering the organisms are higher. Shigella is usually 
isolated from faecal specimens by conventional culture methods followed by 
identification by biochemical tests and serological agglutination assays (WHO, 1987). 
Ideally, patients’ specimens should be analyzed within 2 to 4 hours after sample 
collection. Specimens that cannot be processed within this time should be stored at 
4°C in transport media (buffered glycerol saline or Cary-Blair medium). Isolation and 
identification of Shigella can be greatly enhanced when optimal laboratory media and 
techniques are employed. Since Shigella is a very fastidious organism, appropriate 
collection, rapid transport to the laboratory and rapid plating of the sample are 
important criteria for successful isolation (Shears, 1996). Such conditions are often 
difficult to attain, especially in developing countries. Therefore, the recovery rate of 
Shigella is usually low. As a result, shigellosis remains undiagnosed in a significant 
number of patients (Echeverria et al., 1992). 
 
1.3.2.2.2 (a) Inoculation of selective media  
Isolation of Shigella usually involves an initial streaking for isolation on differential or 
selective media with aerobic incubation to inhibit the growth of the anaerobic normal 
flora. Faeces specimens or rectal swabs are inoculated onto primary isolation media 
such as MAC, DCA, XLD, HEK or SS agar. However, S. dysenteriae type 1 and S. 
sonnei do not grow well on SS agar. These selective media contain bile salts to inhibit 
the growth of other Gram-negative bacteria and pH indicators to differentiate lactose 
fermenters (Coliforms) from non-lactose fermenters (Shigella spp.). Liquid enrichment 
broth (Hajna Gram-negative broth or selenite F broth) may also be inoculated with the 
stool specimen and subcultured onto the selective agar after a short growth period. 
 
For optimal isolation of Shigella, two different selective media should be used. This 
normally include a low selective general purpose plating medium such as  MAC agar, 
and a more selective plating medium, such as DCA, XLD or HEK agar. Selective media 
 15
may be inoculated with a faecal swab, rectal swab or with a single drop of liquid faecal 
suspension and incubated at 37°C for 18 to 24 hours. Characteristics of the colonies 
appearance on the selective media are as described in the section 1.1.4.2. Suspected 
colonies were then identified using biochemical and serological tests. 
 
1.3.2.2.2 (b) Biochemical screening tests 
Suspected well-isolated colonies from the selective media are inoculated into 
appropriate screening media such as Kligler iron agar (KIA) or triple sugar iron agar 
(TSI), motility medium, MR test medium, citrate agar and urea agar (WHO, 1987). 
Shigella produces an alkaline slant and an acid butt due to the inability to ferment 
lactose aerobically in the slope and the anaerobic fermentation of glucose in the butt, 
and fail to produce H2S gas. However, a few strains of S. flexneri serotype 6 and very 
rare strains of S. boydii produce gas in KIA or TSI. Shigella is negative for motility, 
citrate and urea test, and positive reaction is observed in the MR test. 
 
1.3.2.2.2 (c) Serological identification 
Serological testing is performed for confirmation and species classification of the 
Shigella isolates (Ewing & Lindberg, 1984). It is achieved by slide agglutination test 
using commercially available polyvalent O antigen grouping sera. However, in some 
cases, specific serotype identification is performed by testing with monovalent antisera 
for serotypes and sub-serotypes identification. Each species of Shigella contain a 
distinctive type of O antigen. Agglutination tests is carried out using a clean glass slide 
by emulsifying a portion of the growth from the surface of KIA, TSI, or other non-
selective agar media in a drop of physiological saline. Colonies from selective media 
such as MAC or DCA are not advised to be used for this purpose because it may 
produce false-negative results. A small drop of polyvalent or monovalent antiserum is 
mixed with the suspension to observe for the agglutination reaction. Shigella polyvalent 
antiserum will agglutinate strains of the same serogroup and monovalent antiserum will 
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agglutinate the specific serotype or sub-serotype. Cultures that react serologically and 
show no conflicting results in the biochemical screening tests are reported as positive 
for Shigella. 
 
However, in more than 50% of the patients, the exact pathogen is not identified by stool 
cultures. Recent advances in diagnostic technology make detection faster, more 
convenient, more sensitive and specific than the conventional culture method. 
 
1.3.2.3 Other diagnostic techniques 
1.3.2.3.1 DNA-based method 
Recent advances in molecular biology have introduced new approaches for the rapid 
and sensitive diagnosis of bacterial infections by detecting the presence of pathogen-
specific DNA sequences in clinical specimens without the need for culturing the 
bacteria. Polymerase chain reaction (PCR) represents a powerful tool in studying 
bacterial infections that can amplify the target DNA by a million fold in less than 2 
hours. Moreover PCR technology provides information on the current infection status 
and is independent of the host's immune competency.  
 
In the earlier studies, application of DNA technology to diagnosis Shigella spp. is based 
on identification of DNA segments of a 120 to 140 MDa virulent plasmid that is 
necessary for attachment and invasion of epithelial cells (Sansonetti et al., 1982; 
Sansonetti, 1991). Several sensitive and rapid PCR techniques directed towards the 
virulent genes for the detection of invasive Shigella and EIEC have been reported 
(Frankel et al., 1989; Frankel et al., 1990). These techniques utilize gene probes or 
PCR primers directed towards the specific DNA fragments of the invasion plasmid 
locus (ial) or the genes encoding for the ipaH, and were detected with an alkaline 
phosphatase-labelled oligonucleotide probe. A few studies have utilized the 
immunomagnetic separation techniques to specifically isolate Shigella from faeces and 
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subsequently identified by PCR (Islam & Lindberg, 1992; Achi-Berglund & Lindberg, 
1996; Peng et al., 2002). Application of ELISA method to detect PCR products of ipaH 
gene sequences from Shigella and EIEC in diarrheal stool samples have been 
exploited (Sethabutr et al., 2000). The PCR-ELISA technique allowed screening of 
larger number of specimens and avoided the use of mutagenic reagents. Gaudio and 
colleagues (1997) used the same ipaH PCR system in an epidemiology study of 
shigellosis among dysentery patients and family contacts in Thailand. 
 
Various PCR protocols for the detection of Shigella and EIEC in faeces (Frankel et al. 
1990; Sethabutr et al. 1993; Thiem et al., 2004), food (Lampel et al., 1990; Lampel et 
al., 2000; Li et al., 2005) and environmental samples (Theron et al., 2001) have been 
published. In addition, a PCR assay based on the rfc gene capable of distinguishing 
the various Shigella serotypes and EIEC in faecal samples had been described (Houng 
et al., 1997). A multiplex PCR assay was developed by Aranda and colleagues (2004) 
to classify the diarrheagenic E. coli organisms and Shigella spp. based on the ipaH 
gene sequences. 
 
However, limiting issues that prevent DNA technology from general use in the 
diagnostic laboratory is that it is expensive to perform and requires sophisticated 
equipment, which may not be available in the developing countries. This is of particular 
concern, as most of the Shigella infections are endemic in these parts of the world. 
This technology is both technically demanding and labour-intensive, thus is poorly 
suited for routine practice. Moreover, the presence of PCR inhibitors in the complex 
samples, such as faeces, food and in culture media can inhibit amplification of the 
target genes, thus limiting the usefulness of the PCR technique in diagnosis. Moreover, 
in most cases, cultural enrichment is required prior to analysis. Although PCR products 
visualized with the agarose electrophoresis technique is simple, rapid and more 
sensitive than the conventional diagnostic method, the result is subjective, usually 
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involving the use of a mutagenic ethidium bromide reagent to illuminate the bands, 
requiring special equipment and a limited number of specimens can be processed at 
any one time. 
Various formats of DNA and oligonucleotide microarray techniques have been 
developed and applied to screen multiple microbial organisms in diagnostic assays 
(Wu et al., 2001; Cho & Tiedje, 2002). However, more meticulous and systematic 
assessment and development are needed to understand the full potential of 
microarrays for diagnostic studies. Moreover, such technology requires sophisticated 
instruments to prepare and the result can only be read by laser scanner, thus limiting 
its broad application in common laboratories (reviewed by Zhou, 2003). 
 
1.3.2.3.2 Immunological assay 
Immunological assays have been the most rapid methods for specific identification of 
bacterial infections. These tests employ antibody or antigen recognizing only one or a 
group of bacteria. Recent advances in immunoassay technology make detection faster, 
more convenient, more sensitive and specific than the conventional culture method. 
The highly specific binding of antibody to antigen, plus the simplicity and versatility of 
this reaction, has facilitated the design of a variety of antibody assays. The antibody-
based assays comprise the largest group of rapid methods being used in bacterial 
identification. To date, no reliable rapid method is commercially available for shigellosis 
identification and none are in use routinely in the laboratory. 
 
There are several basic formats of antibody-based assays such as latex agglutination, 
immunodiffusion and enzyme immunoassays (EIA) format. Of the wide range of 
immunoassays available, EIA is the most common format used for testing large 
numbers of samples and is suitable for automation and quantification. There are many 
different EIA methods that have been developed for diagnosis of shigellosis. For 
example, a monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) 
 19
has been developed using a 43 kDa invasion plasmid-coded protein antigen (IpaC) to 
identify EIEC and Shigella strains in faecal samples from children in Kuwait (Pal et al., 
1997). ELISA techniques have been employed for the detection of serum and urine 
antibodies of various immunoglobulin classes developed against Shigella serogroup 
specific LPS (Cohen et al., 1989; Cohen et al., 1996; Shamlal et al., 1997). It has been 
reported that the increase in the level of serum IgA to Shigella LPS indicates a recent 
infection,  in which IgA levels were highest 2 weeks after infection and declined to initial 
levels within 2.5 months (Cohen et al., 1989). Another ELISA method was developed 
using purified recombinant IpaD protein for identification of Shigella spp. (Oaks et al., 
1996). Besides that, simple and inexpensive ELISA methods have been developed, 
which provides an alternative to the conventional virulent tests such as 
keratoconjunctivitis or in vitro penetration of the cultured mammalian cells (Pal et al., 
1983; Pal et al., 1985). A rapid latex agglutination procedure, the Wellcolex Colour 
Shigella tests, have been developed for grouping Shigella using an antibody attached 
to multicoloured latex particles (Bouvet & Jeanjean, 1992). To indicate the related 
Shigella species, blue or red colour agglutination is observed when the corresponding 
antibodies coated to the latex particles recognize the specific antigen. Besides that, 
colony blot immunoassays have been developed to detect EIEC and Shigella in stool 
and water samples (Szakal et al., 2001; Szakal et al., 2003).  
 
Another simple format is the dot-EIA test, in which specific antigens or antibodies are 
immobilized on a membrane (usually nitrocellulose) and the reaction is observed by 
enzyme activity. In a previous study, an antigenic membrane protein of 35 kDa 
molecular weight, which is specific to IgA in sera of patients infected with Shigella spp. 
had been demonstrated (Kirnpal-Kaur, 2001). A dot-EIA was developed using this 
protein and laboratory diagnostic result of this test could be obtained in 3 hours to 
diagnose Shigella infection. 
 
 20
However, there are many limiting factors that prevent the immunoassay tests for 
routine laboratory diagnostic application. Two major factors that determine the efficacy 
of immunoassay is the efficiency of antigen-antibody complex formation and the ability 
to detect these complexes. Regardless of the format, the specificity of an immunoassay 
is dependent on the reaction between antibody and antigen. The limitations of EIA 
involve the specificity and affinity of the antibodies used, cross-reactivity, the specific 
activity of the enzyme and substrate employed, and efficiency of the signal detection. 
Some of the assays require growth in an enrichment medium before analysis. Besides 
that, the disadvantages of EIA are that interpretation of the test results requires 
experienced staff, and is time consuming, therefore fewer tests can be run per day. 
The major disadvantages of ELISA are that it is relatively time-consuming, labour-
intensive and to some extent is temperature-dependent. The sensitivity and specificity 
of the assays depend mainly on the type of antigens used. Assays that employ 
recombinant protein or synthetic peptide antigens tend to be more specific than using 
whole or disrupted particles.  
 
Thus, the need for a more rapid, sensitive and portable assay remains as urgent as 
ever, providing the impetus for the development of next generation technologies. 
Recently new rapid, membrane-based antibody assay, which is based on the 
technology developed for home pregnancy tests have been devised for diagnosis of 
infectious agents. It is known as the immunochromatography test (ICT), lateral flow 
assay or dipstick test. ICT have been available on the commercial market for more than 
20 years, which was first developed to detect abused drugs and for pregnancy testing. 
It is simple to use and require minimal training, thus resulting in saving labour, time and 
materials. The detecting antibody is usually coupled to coloured latex beads or to 
colloidal gold instead of enzyme conjugates. In this test, reactants move by capillary 
action along a narrow rectangular membrane strip. The sample is applied at one end 
and traverses the strip, coming into contact first with detecting antibodies (conjugated 
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to gold particles, normally 10 to 60 nm diameter) and subsequently with capture 
antigens or antibodies that have been dried onto the membranes. If the sample 
contains the corresponding antibodies or antigens, it will form a visible line as it 
accumulates at the position of the captured lines. The test results can be read by the 
appearance of the bands directly with eye, which ensures the convenience of the assay 
on-site. Studies have reported that immunochromatography test is extremely simple, 
require no washing or manipulation, reliable and rapid that the test can be completed 
within 5 to 15 minutes (Paek et al., 2000; Shyu et al., 2002; Chiao et al., 2004). A 
number of the immunochromatography tests have been developed for the detection of 
bacterial or parasitic infections such as TYPHIRAPID™ for diagnosis of typhoid, 
BrugiaRapid™ for diagnosis of filariasis (Rahmah et al., 2001; Lammie et al., 2004), 
brucellosis (Smits et al., 1999b; Smits et al., 2003) and malaria (reviewed by Moody, 
2002). 
 
1.4 Rationale of the study 
Shigella spp. are one of the most important etiological agents of dysentery for people 
who are living in developing countries and travellers from industrialized countries. S. 
flexneri has been the most frequently isolated species especially in the developing 
countries (Taylor et. al., 1991; Faruque et al., 2002; Lee & Puthucheary, 2003; Ludin et 
al., 2003; Niyogi & Pazhani, 2003). Major obstacles in controlling this pathogen are the 
high contagiousness of the disease and the emergence of multi-resistance 
characteristic to the commonly prescribed antibiotics. As shigellosis is highly 
contagious, it is crucial to develop a rapid method for identifying the bacteria in order to 
limit and control outbreaks. Immediate identification of the pathogen in clinical samples 
is critical to ensure proper clinical treatment, management of the patients and for 
epidemiological investigations. 
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Current laboratory diagnostic method used to diagnose Shigella infection relied on the 
time-consuming growth in culture media, followed by isolation, biochemical and 
serological identification. Nevertheless, the selection of the pathogenic bacterial 
colonies on selective media is time consuming and could be missed if their numbers 
are low in the sample particularly due to the delay in sample transportation. The 
sensitivity of this culture method is relatively low, thus increasing the need for 
alternative diagnostic methods. Various studies have reported that the sensitivity of the 
culture method is 54% (Dutta et al., 2001) and 74% (Islam et al., 1998), when 
compared to other diagnostic methods. As mentioned earlier, there are a number of 
DNA-based tests and immunoassay tests that have been developed for the diagnosis 
of shigellosis. Detection methods based on nucleic acid, such as the PCR have shown 
tremendous potential and have been increasingly exploited. However, among the 
limitations of DNA-based tests and immunoassays are relatively time-consuming, 
labour-intensive and require growth in enrichment medium before analysis.  
 
The relatively low sensitivity and the difficulty in performing the current diagnostic 
procedure for shigellosis have called for an alternative diagnostic method for this 
disease. A rapid, simple and reliable diagnostic test is highly desired. One such method 
involves detection of specific antibodies in clinical specimens. There is a need for the 
development of next generation immunoassay technologies which provide a more 
rapid, sensitive and portable assays. The ICT technology which is based on the 
membrane-based antibody assays has been shown to be a potential tool for the 
diagnosis of pathogens (Rahmah et al., 2001; Smits et al., 2003; Lammie et al., 2004). 
The advantages of the immunochromatography test over culture method are rapidity, 
simplicity, do not require expensive equipment, do not require cold chain for 
transportation, enhanced sensitivity and specificity for early diagnosis and the test can 
be performed at point of care. However, there is no report on diagnostic applications 
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employing the immunochromatography concept that have been developed for 
diagnosis of shigellosis. 
A rapid and reliable diagnostic assay would significantly improve effective management 
of the disease especially among young children and the elderly. Although oral 
rehydration therapy has a role to play in the treatment of dysentery, it is often 
necessary to treat patients with specific antibiotics at the early stage to control 
outbreaks of this contagious disease and prevent further complications. This 
information is important in reducing the morbidity and mortality and in the selection of 
appropriate antibiotics in the management of extraintestinal complications. 
 
In a previous study, an antigenic membrane protein that is specific to IgA in the sera of 
patients infected with Shigella had been demonstrated. A dot-EIA was developed using 
this specific protein and laboratory diagnostic result can be attained in 3 hours. In view 
of the fact that the current global diagnostic trend is moving towards rapid 
immunochromatography platform, there is a need to strategically convert this test to 
achieve a more rapid laboratory diagnosis. This study will be focused on the S. flexneri 
since it is the most common species isolated from patients in endemic area. 
 
1.5 Objectives of the study 
The ability to produce indigenous diagnostic tests for shigellosis that are novel, specific 
yet cost-effective would now provide a huge impact on public health management not 
only in Malaysia but also for all developing countries affected. Thus the main aim of this 
study is to optimize the conditions needed to provide sufficient purified recombinant 35 
kDa protein and to exploit its application in developing a rapid immunochromatography 
test, as an alternative diagnostic test for the detection of anti-S. flexneri IgA antibody.  
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To achieve these goals, specific objectives of the study include: 
 
1. To determine the complete amino acid and nucleic acid sequences encoding for 
the 35 kDa protein. Amino terminal (N-terminal) amino acid sequence will be 
determined and homology search will be performed against the S. flexneri 
whole genome sequence database. The identified amino acid sequence will be 
further validated by MALDI-ToF technique. The amino acid sequence of the 
protein will be further characterized to determine the presence of signal peptide. 
 
2. To construct and evaluate a recombinant plasmid vector for the expression of 
the recombinant 35 kDa protein of S. flexneri in E. coli. This study will describe 
the cloning process of the gene encoding the 35 kDa protein of S. flexneri using 
the pET 43.1 Ek/LIC vector. This recombinant clone will be verified by restriction 
enzyme digestion and DNA sequencing technique. Optimization studies of the 
protein expression in E. coli BL21 (DE3) will be performed to generate high 
concentrations of recombinant protein. The target protein will be verified by 
SDS-PAGE analysis and its immunogenicity will be determined by Western blot 
technique.  
 
3. To purify the recombinant 35 kDa protein of S. flexneri. In this study, 
immobilized metal affinity chromatography (IMAC) technology will be used to 
purify the histidine-tagged recombinant protein. Initially, small-scale protein 
purification will be performed using a batch column technique. The purification 
conditions will be optimized in advance and consequently the protein 
purification protocol will be up-scaled using FPLC system to generate high 
concentrations of purified protein in a large quantity. 
4. To exploit the usage of the purified recombinant protein in the development of 
immunochromatography test for the detection of anti-S. flexneri IgA antibody in 
